Combining THC and Opioids Did Not Improve Pain Relief for Knee Osteoarthritis

In a within-subject, double-blind trial, hydromorphone showed some analgesic effects on specific pain measures (pressure pain threshold, mechanical temporal summation) but neither drug reduced clinical pain severity or most experimentally induced pain measures. Critically, combining dronabinol and hydromorphone did not produce synergistic analgesia, contradicting preclinical data. The combination impaired working memory reaction time, produced higher subjective drug effects and "High" ratings, and caused more nausea than either drug alone.

Within-subject, double-blind, randomized, placebo-controlled trial. 21 adults (57% women, mean age 63.4) with knee osteoarthritis received four oral drug combinations across separate sessions: placebo, hydromorphone (2 mg), dronabinol (10 mg), and both combined. Assessed clinical and experimental pain, physical function, cognition, subjective effects, and adverse events at baseline and 60-240 minutes.

This well-designed trial directly tests the popular hypothesis that combining cannabinoids with opioids could reduce pain more effectively while potentially lowering opioid doses. The negative result challenges this clinical strategy, at least for acute dosing in chronic pain populations.

The disconnect between promising preclinical combination studies and this negative clinical result highlights a common challenge in translating animal pain research to human chronic pain conditions. Knee osteoarthritis may involve pain mechanisms that are not responsive to acute opioid-cannabinoid combinations.

Small sample size (N=21). Single acute doses tested; chronic dosing might yield different results. Relatively low doses of both drugs. KOA represents one specific type of chronic pain. Within-subject design is a strength but may have learning effects across sessions.